The results of this study highlight the potential of SHP agonists in the treatment of liver fibrosis, however the fact that SHP agonism requires a FXR ligand to modulate the expression of pro-fibrogenetic genes in human LX2 cells, suggest that a combination therapy might be necessary in clinical settings. This evidence concerns the gene NR1H4 and Hepatic fibrosis.